Optimizing Cancer Care in Developing Countries: Strategies for Prevention and Early Diagnosis

Jump To Section

• The Cancer Epidemic in the Developing World
• The Primacy of Prevention and Early Detection
• AFROX Charity and the Journal of Global Oncology
• Leveraging Mobile Technology and Innovation
• Designing Low-Cost Cancer Treatment Solutions
• Future Challenges and Opportunities

The Cancer Epidemic in the Developing World

Cancer treatment presents a monumental challenge in developing countries across Africa, Asia, the Middle East, and South America. Dr. David Kerr, MD, a renowned oncologist, highlights a critical statistic: over 70% of new cancer cases occur in the developing world. The established high-cost cancer treatment system prevalent in the United States and Western Europe is simply not achievable in these resource-limited settings. This disparity creates an urgent need for a fundamentally different approach to oncology care that is both effective and affordable.

Dr. Anton Titov, MD, the interviewer, notes the expense of modern cancer diagnostics and treatment, underscoring why a new system must be developed. The conversation with Dr. Kerr centers on building basic blocks of modern cancer care that are tailored to the economic and infrastructural realities of these regions.

The Primacy of Prevention and Early Detection

Early cancer diagnosis is the cornerstone of effective treatment, yet it remains a significant hurdle in developing nations. Dr. David Kerr, MD, provides a stark illustration of the problem, noting that 80% to 90% of cancer patients in sub-Saharan Africa present with Stage 4 cancer. At such an advanced stage, the impact of any treatment is minimal, regardless of the healthcare system. This makes a focus on cancer prevention and early detection the most critical strategy for improving survival rates.

Shifting resources toward these areas can make the most significant difference in saving lives. Dr. Kerr argues that this approach represents "amplified good," where public health initiatives can benefit populations on a scale that individual patient care cannot. This strategy is essential for controlling the cancer epidemic in low-income countries.

AFROX Charity and the Journal of Global Oncology

Dr. David Kerr, MD, is actively involved in practical efforts to improve cancer care through initiatives like the charity AFROX (afrox.org). This organization works to establish best practices in cancer treatment specifically within Africa. Furthermore, Dr. Kerr’s role as Editor-in-Chief of the Journal of Global Oncology is pivotal. This publication provides a vital platform for cancer researchers and doctors working in poorer countries to share their work and contribute to global knowledge.

The journal also serves as a means to campaign on behalf of oncology colleagues facing immense challenges, including cultural barriers where some languages lack a word for cancer. Dr. Anton Titov, MD, discusses these efforts as crucial for building a supportive global oncology community and integrating valuable insights from the developing world into mainstream cancer care discourse.

Leveraging Mobile Technology and Innovation

Innovation in point-of-care technology offers a promising path forward for cancer diagnosis in developing countries. Dr. Anton Titov, MD, draws a powerful analogy to telecommunications, where many Asian and African nations became "mobile first," bypassing expensive landline infrastructure. Medicine, he suggests, could develop in a similar leapfrog fashion. Dr. David Kerr, MD, agrees, confirming that mobile phone connectivity is better in Rwanda than in England, demonstrating how technology adapts to its environment.

This lateral thinking involves developing handheld, intuitive cancer screening devices that can be used at the point of care without requiring sophisticated training. The goal is to create medical technology that is accessible, affordable, and easy to use, thereby bringing the costs of healthcare down and enabling widespread early detection.

Designing Low-Cost Cancer Treatment Solutions

The evolution of Western medicine toward ever more expensive and complex treatments often yields only marginal benefits, a trend that is unsustainable for the developing world. Dr. David Kerr, MD, calls for a fundamental rethinking of medical technology design. Instead of developing the next expensive cancer medication or complicated radiation therapy machine, the challenge is to create very low-cost alternatives, such as simplified linear accelerators instead of proton beam machines.

Dr. Kerr questions whether full gene sequencing is necessary to deliver precision medicine in Africa, suggesting that the key is to identify and focus on the most critical, cost-effective elements. This philosophy of designing for low-cost and high usability is essential for achieving greater good and making cancer treatment truly accessible.

Future Challenges and Opportunities

The work of optimizing cancer care in developing countries presents significant challenges but also immense opportunities to save lives. Dr. David Kerr, MD, emphasizes the need for greater understanding and volunteer efforts from oncologists in developed nations. The reward for this work extends beyond financial return; it is the profound satisfaction of helping less fortunate populations and making a tangible, large-scale impact.

Dr. Anton Titov, MD, concludes the discussion by highlighting the importance of this approach. The integration of prevention, point-of-care diagnostics, and innovative, low-cost treatment solutions is the most viable strategy to combat the growing cancer epidemic in Africa, the Middle East, Asia, and South America, ultimately saving both money and lives.

Full Transcript

Dr. Anton Titov, MD: Dr. David J. Kerr has extensive experience in the organization of cancer treatment in Africa, the Middle East, South America, and Asia. Why is point-of-care diagnostics crucial for early cancer diagnosis? How can we ensure better and cheaper treatment of cancer in developing countries?

The Journal of Global Oncology helps to spread the work of cancer researchers and doctors from developing countries. Cancer care in developing countries. Emerging markets and developing countries in Africa, Asia, the Middle East, and Russia or Eastern Europe have limited resources to fight cancer, including colorectal cancer.

Cancer treatment in Africa, Asia, South America, and Eastern Europe must be more efficient and rely on point-of-care diagnosis and treatment. The Journal of Global Oncology's new editor is Dr. David J. Kerr, MD. The cancer treatment charity AFROX (afrox.org) helps establish best practices in cancer treatment in Africa.

Use of mobile phone networks and point-of-care technology to diagnose cancer at the earliest stages offers the best hope for cancer treatment in Africa, the Middle East, Asia, and Russia or CIS.

Dr. Anton Titov, MD: You have a particular interest and a very impressive track record in the organization of international cancer care. Cancer treatment and cancer diagnostics are very expensive. For most of the world outside of the United States and Western Europe, the established system of very high-cost cancer treatment is just not achievable.

But over 70% of new cancer cases occur in the developing world. It is important to know that many cancer cases are preventable in the first place. Cancer prevention is a very important strategy for controlling cancer in the developing world.

Nevertheless, for treating cancer patients in the developing world, another system has to be established. You have extensive experience in cancer care organization in Africa and the Middle East. You recently led a conference on the treatment of cancer in Africa.

How should cancer care, cancer diagnostics, and cancer treatment be approached in emerging markets?

Dr. David Kerr, MD: Organization of international cancer care has become a dominating theme of the later part of my career. We all look back at our careers and decide what good we've done, if anything. I like the concept of "amplified good."

I can do this much—a little—by treating individual colorectal cancer patients. I sit across from the colon cancer patient, I communicate cancer treatment decisions clearly, I love that aspect of clinical medicine. My colorectal cancer research can help hundreds of thousands of patients. This has a larger impact on the world.

There is an even larger potential in work to develop national cancer treatment plans. We must develop health policies to treat cancer. We must work with health ministries and presidents of poorer countries.

Cancer treatment organization has the potential to save hundreds of thousands of lives. To me, that is what the professional gift is. It is a gift of life. We have to pay attention to the epidemic of cancer in low-income countries.

We have to establish the basic building blocks of modern cancer care. Then we can change cancer care in the developing world for good.

Dr. Anton Titov, MD: Where do we start across the spectrum of cancer control? We can start by raising awareness of the cancer epidemic. Prevention of cancer and early cancer diagnostics are most important.

Dr. David Kerr, MD: 80% to 90% of cancer patients in sub-Saharan Africa present with Stage 4 cancer. It does not matter where those patients with Stage 4 cancer would be treated. The impact of cancer treatment in such advanced Stage 4 cancer is small in any cancer treatment system.

Focus on prevention and early detection of cancer. This will make the most difference in these resource-challenged countries. I work with colleagues in sub-Saharan Africa. We have a small charity, Afrox (www.afrox.org).

I am honored by ASCO, the American Society of Clinical Oncology, to be made Editor-in-Chief of the new Journal of Global Oncology. This journal gives voice to our cancer treatment colleagues who are working in these poorer countries.

Treating cancer in Africa is difficult work. Some African languages do not have a word for cancer. Some dialects do not name cancer as a disease.

The Journal of Global Oncology will be a means for us to campaign on behalf of our oncology colleagues working in Africa and other countries. The journal will bring their cancer research work to the world. But we are hungry to add their knowledge to the global knowledge about cancer treatment.

We will support our international colleagues in this work. This is really important work. We require greater understanding and volunteer efforts from our cancer treatment colleagues working in the developed countries.

Dr. Anton Titov, MD: It's important to emphasize from examples such as telecommunications that a lot of the Asian and African countries are "mobile first." They bypass high-cost landline infrastructure. They go straight for mobile technology.

Maybe medicine will develop in a similar fashion in Africa and Asia.

Dr. David Kerr, MD: You must have enough knowledge in medicine. You must focus on prevention and early detection of disease. Then you can bring the costs of healthcare down. That is a trend in the world for cancer treatment and other medical care.

It is a good analogy. Mobile phone connectivity is better in Rwanda than in England. Technology adapts to the environment. We must be more lateral in our thinking.

Applying all modern Western medicine to Africa does not work. It doesn't work.

Dr. Anton Titov, MD: We need to adapt the ideas and concepts that we have on cancer diagnosis and cancer treatment. We need to involve engineers in handheld cancer screening device development. All medical technology has to work at the point of care.

This requires thought, innovation, and invention. The reward of this work in cancer treatment is not only financial. There has to be some commercial return, it is true. But perhaps the sense that we are helping our brothers and sisters who are less well-off is a large reward in itself.

Dr. Anton Titov, MD: This approach is very important. Perhaps it brings analogies from the computer and consumer products world: the usability of products, the user experience. As you mentioned, the importance of handheld diagnostic equipment—something that can be intuitively used.

Intuitive use of medical devices means they can be used by many more patients. This is in contrast to equipment that requires sophisticated training.

Dr. David Kerr, MD: I agree. We need to set challenges for ourselves. We can avoid developing the next most expensive cancer medication or the next most complicated set of radiation therapy machines. That is the way medicine evolves in the West.

Medicine becomes ever more expensive and complex in the West. Often it brings only marginal results. We need to step back. We need to design very low-cost linear accelerators rather than proton beam machines.

We can achieve much more good with that strategy. I am not a physicist or radiation oncologist, but there is a challenge in that. There is also a challenge in cancer diagnostics.

Do we need all gene sequencing to come up with key elements to deliver precision medicine to Africa? I guess not. These are some big challenges that we now have in cancer treatment in Africa.

Dr. Anton Titov, MD: This is very important work that you are doing. I am glad we have had a chance to discuss it. Cancer treatment in Africa, the Middle East, Russia, South America—what are the leading challenges? Point of care and early cancer diagnostics save money and lives.